Palonosetron on Days 1 and 5
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bleomycin
/ adverse effects
Cisplatin
/ adverse effects
Drug Administration Schedule
Etoposide
/ adverse effects
Female
Granisetron
/ administration & dosage
Humans
Male
Middle Aged
Nausea
/ chemically induced
Neoplasms, Germ Cell and Embryonal
/ complications
Palonosetron
/ administration & dosage
Vomiting
/ chemically induced
Young Adult
Germ cell tumour
chemotherapy-induced nausea and vomiting
granisetron
palonosetron
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
04
01
2019
revised:
28
01
2019
accepted:
29
01
2019
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
6
6
2019
Statut:
ppublish
Résumé
The control of chemotherapy-induced nausea and vomiting during bleomycin, etoposide, and cisplatin (BEP) treatment is important for maintaining treatment intensity. The effects of palonosetron and granisetron were compared in BEP chemotherapy. The administration of palonosetron on days 1 and 5 (Pal method) and granisetron daily (days 1-5, Gra method) were compared in terms of their efficacy and cost-effectiveness. Additional rescue antiemetic agents were used in 15 of 32 and 30 of 30 cycles in the Pal and Gra method groups, respectively (p<0.05). The complete response rate, defined as no vomiting and no rescue agent usage, in each cycle, was 50% and 0% in the Pal and Gra method groups, respectively (p<0.05). The average cost of antiemetic agents in a cycle was 50,759 and 54,555 yen in the Pal and Gra method groups, respectively (p<0.05). The Pal method may be the standard method in BEP.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The control of chemotherapy-induced nausea and vomiting during bleomycin, etoposide, and cisplatin (BEP) treatment is important for maintaining treatment intensity. The effects of palonosetron and granisetron were compared in BEP chemotherapy.
PATIENTS AND METHODS
METHODS
The administration of palonosetron on days 1 and 5 (Pal method) and granisetron daily (days 1-5, Gra method) were compared in terms of their efficacy and cost-effectiveness.
RESULTS
RESULTS
Additional rescue antiemetic agents were used in 15 of 32 and 30 of 30 cycles in the Pal and Gra method groups, respectively (p<0.05). The complete response rate, defined as no vomiting and no rescue agent usage, in each cycle, was 50% and 0% in the Pal and Gra method groups, respectively (p<0.05). The average cost of antiemetic agents in a cycle was 50,759 and 54,555 yen in the Pal and Gra method groups, respectively (p<0.05).
CONCLUSION
CONCLUSIONS
The Pal method may be the standard method in BEP.
Identifiants
pubmed: 30804153
pii: 33/2/643
doi: 10.21873/invivo.11522
pmc: PMC6506324
doi:
Substances chimiques
Bleomycin
11056-06-7
Palonosetron
5D06587D6R
Etoposide
6PLQ3CP4P3
Cisplatin
Q20Q21Q62J
Granisetron
WZG3J2MCOL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-647Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Oncol. 2001 Mar 15;19(6):1629-40
pubmed: 11250991
Cancer. 2003 Apr 15;97(8):1869-75
pubmed: 12673712
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
Eur J Cancer. 2006 May;42(7):820-6
pubmed: 16574403
Support Care Cancer. 2007 Nov;15(11):1293-1300
pubmed: 17436025
Lancet Oncol. 2009 Feb;10(2):115-24
pubmed: 19135415
Ann Oncol. 2009 Nov;20(11):1860-6
pubmed: 19561037
J Clin Oncol. 1990 Feb;8(2):337-41
pubmed: 2153767
Eur J Pharmacol. 2014 Jan 5;722:26-37
pubmed: 24184669
N Engl J Med. 1987 Jun 4;316(23):1435-40
pubmed: 2437455
Support Care Cancer. 2014 Aug;22(8):2161-6
pubmed: 24652048
Support Care Cancer. 2016 Jul;24(7):2837-42
pubmed: 26838019
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
Nat Rev Dis Primers. 2018 Oct 5;4(1):29
pubmed: 30291251
J Clin Oncol. 1985 Oct;3(10):1379-84
pubmed: 4045527
Oncology. 1996 Jun;53 Suppl 1:26-31
pubmed: 8692547
Oncology. 1996 Jun;53 Suppl 1:39-45
pubmed: 8692549
Oncology. 1996 Jun;53 Suppl 1:73-7
pubmed: 8692555
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
J Clin Oncol. 1997 Jul;15(7):2559-63
pubmed: 9215825
J Clin Oncol. 1998 Apr;16(4):1287-93
pubmed: 9552027